{"filing":{"accession_number":"0001493152-26-041872","cik":"0001595353","ticker":"GLMD","company_name":"Galmed Pharmaceuticals Ltd.","form":"6-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595353/000149315226041872/form6-k.htm"},"events":[{"id":32195,"run_id":29577,"accession_number":"0001493152-26-041872","anchor_item_number":"EX-99.1","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Galmed Pharmaceuticals announced a corporate rebranding to EoCene Ltd. with a ticker symbol change from GLMD to EOCN, and terminated a $20 million Standby Equity Purchase Agreement with Yorkville (which had raised $7.3 million). The company regained Nasdaq compliance as part of this strategic pivot toward a GI-focused medtech/biopharmaceutical platform following the Colospan acquisition.","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-09-09","form":"6-K","submitted_at":null,"items":[{"id":35308,"accession_number":"0001493152-26-041872","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This exhibit announces a corporate rebranding from Galmed Pharmaceuticals to EoCene Ltd., including a ticker symbol change from GLMD to EOCN, and termination of a $20 million Standby Equity Purchase Agreement with Yorkville. While the rebranding itself is primarily a governance/administrative matter, the termination of the SEPA (which had raised $7.3 million) and the company's regained Nasdaq compliance are material to investors' assessment of the registrant's capital structure and listing status. The rebranding reflects a strategic pivot toward a GI-focused medtech/biopharmaceutical platform following the Colospan acquisition, which is operationally significant but disclosed here as a corporate identity matter rather than as a discrete M\u0026A event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:40:49.382044+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32196,"run_id":29577,"accession_number":"0001493152-26-041872","anchor_item_number":"EX-99.2","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"summary":"The company filed its Amended and Restated Articles of Association, a routine governance document setting forth organizational structure, shareholder rights, share capital provisions, and procedural rules for meetings and transfers.","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-09-09","form":"6-K","submitted_at":null,"items":[{"id":35309,"accession_number":"0001493152-26-041872","item_number":"EX-99.2","item_title":"ex99-2.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This exhibit is the Amended and Restated Articles of Association of Eocene Ltd., a governance document setting forth the company's organizational structure, shareholder rights, share capital provisions, and procedural rules for meetings and transfers. While governance-related, it is a routine administrative disclosure of bylaws/articles rather than a material corporate event affecting investor assessment. No substantive changes to control, compensation, or strategic direction are disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:40:49.382044+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35308,"accession_number":"0001493152-26-041872","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This exhibit announces a corporate rebranding from Galmed Pharmaceuticals to EoCene Ltd., including a ticker symbol change from GLMD to EOCN, and termination of a $20 million Standby Equity Purchase Agreement with Yorkville. While the rebranding itself is primarily a governance/administrative matter, the termination of the SEPA (which had raised $7.3 million) and the company's regained Nasdaq compliance are material to investors' assessment of the registrant's capital structure and listing status. The rebranding reflects a strategic pivot toward a GI-focused medtech/biopharmaceutical platform following the Colospan acquisition, which is operationally significant but disclosed here as a corporate identity matter rather than as a discrete M\u0026A event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:40:49.382044+00:00","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-09-09"},{"id":35309,"accession_number":"0001493152-26-041872","item_number":"EX-99.2","item_title":"ex99-2.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This exhibit is the Amended and Restated Articles of Association of Eocene Ltd., a governance document setting forth the company's organizational structure, shareholder rights, share capital provisions, and procedural rules for meetings and transfers. While governance-related, it is a routine administrative disclosure of bylaws/articles rather than a material corporate event affecting investor assessment. No substantive changes to control, compensation, or strategic direction are disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:40:49.382044+00:00","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-09-09"}]}